Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02534350 · ClinicalTrials.gov registry record · Phase 2
Presatovir in Lung Transplant (LT) Recipients With Respiratory Syncytial Virus (RSV) Infection
A Phase 2 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
NCT02534350 is a Phase 2 study that has completed, run by Gilead Sciences. The registered enrollment target is 61 participants.
The verdict
NCT02534350, a Phase 2 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the effect of presatovir on nasal respiratory syncytial virus (RSV) viral load in RSV-positive lung transplant (LT) recipients with acute respiratory symptoms.
Interventions
- DRUG Placebo
- DRUG Presatovir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2015-12-31 |
| Est. Completion | 2017-09-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02534350
The ClinicalTrials.gov registry entry for NCT02534350 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02534350 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02534350 about?
NCT02534350 is a clinical study titled "Presatovir in Lung Transplant (LT) Recipients With Respiratory Syncytial Virus (RSV) Infection". The primary objective of this study is to evaluate the effect of presatovir on nasal respiratory syncytial virus (RSV) viral load in RSV-positive lung transplant (LT) recipients with acute respiratory symptoms.
What is the current status of trial NCT02534350?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2015-12-31. Estimated completion is 2017-09-27.
What interventions are being tested in trial NCT02534350?
The interventions under investigation include: Placebo (DRUG), Presatovir (DRUG).
Who is sponsoring clinical trial NCT02534350?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.